Regulonix

Regulonix is an early-stage biotechnology company developing non-opioid drugs for chronic pain. The company's science indirectly targets well-established pain ion channels using a novel drug delivery approach, supported by a team with world-class expertise in ion-channel biology and pain channel research. Regulonix is backed by UA Venture Capital, indicating ties to the University of Arizona ecosystem.